ReviewDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2010
[Complicated intra-abdominal infections: pathogens, resistance. Recommendations of the Infectliga on antbiotic therapy].
Review in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 27 citations in OpenAlex.
- Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model.Antibiotics (Basel, Switzerland) · 2023Article
- Low-Dose CT Fluoroscopy-Guided Drainage of Deep Pelvic Fluid Collections after Colorectal Cancer Surgery: Technical Success, Clinical Outcome and Safety in 40 Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- The Need of Antimicrobial Stewardship in Post-Operative Infectious Complications of Abdominal Surgery.Visceral medicine · 2022Review
- Damage control surgery in perforated diverticulitis: ongoing peritonitis at second surgery predicts a worse outcome.International journal of colorectal disease · 2018Article
- Bad bacteria in acute appendicitis: rare but relevant.International journal of colorectal disease · 2017Article
- [Enterococci and surgical site infections : Causal agent or harmless commensals?]Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2017Review
- Perioperative Antibiotic Prophylaxis and Antimicrobial Therapy of Intra-Abdominal Infections.Viszeralmedizin · 2014Review
- Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome.BMC infectious diseases · 2014Article
- Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria.European journal of medical research · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intra-abdominal infections are generally the result of invasion and multiplication of enteric bacteria in the wall of a hollow viscus within the abdomen to produce peritonitis or abscess. When the infection extends into the peritoneal cavity or another normally sterile region of the abdominal cavity, the infection is described as a "complicated" intra-abdominal infection. Treatment of patients with complicated intra-abdominal infections involves antimicrobial therapy, generally in conjunction with an appropriate and timely surgical source control. Nearly all intra-abdominal infections are caused by multiple microorganisms that constitute the intestinal flora (aerobes and facultative and obligate anaerobes, with Enterobacteriaceae, enterococci and Bacteroides fragilis isolated most frequently). The emergence of drug resistance (e.g. ESBL-producing Enterobacteriaceae or resistant enterococci and staphylococci) poses a substantial threat to patients with surgical infections. Especially in patients with nosocomially acquired infections inadequate empiric antibiotic treatment is associated with treatment failure and death. In patients at risk broader spectrum antibiotic regimens with coverage of resistant Gram-negative bacilli and anaerobes and Gram-positive bacteria such as enterococci (including VRE) and staphylococci should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.